S&P 500 index data: S&P 500 Copyright ©
All data supplied by Morningstar Real-Time Data. U.S. intraday real-time exchange quotes are sourced from BATS when available. End-of-day quotes for Nasdaq, NYSE, and Amex securities will appear 15 minutes after close. Graph times are Eastern Standard. © Copyright Morningstar, Inc .
|Synthetic Biologics' Academic Collaborator to Present Novel Monoclonal Antibody Combination for Treating Whooping Cough (Pertussis) at Gordon Research Conference (2014/7/21)|
|Synthetic Biologics Highlights SYN-005 Data Presented at the 54th ICAAC from Novel Whooping Cough (Pertussis) Program|
|Synthetic Biologics to Webcast September 16, 2014 Irritable Bowel Syndrome (IBS) Investor Day|
|Synthetic Biologics to Host Irritable Bowel Syndrome (IBS) Investor Day|
|Synthetic Biologics and FUJIFILM Diosynth Biotechnologies UK Announce Significant Improvement in API Manufacturing of SYN-004 for the Prevention of C. difficile (2014/8/28)|
|Synthetic Biologics' Academic Collaborator to Present Novel Monoclonal Antibody Combination for Treatment of Whooping Cough (Pertussis) at 54th ICAAC|
|Synthetic Biologics Reports Second Quarter 2014 Financial Results and Operational Highlights (2014/8/14)|
|Synthetic Biologics on Track to Initiate Clinical Program for SYN-004 to Protect Against C. difficile (2014/8/5)|
|Synthetic Biologics' Statin-Class Candidate for Constipation-Predominant Irritable Bowel Syndrome Detailed at Company's Investor Day|
|Synthetic Biologics to Initiate Clinical Trials of SYN-004 in 4Q 2014 to Prevent Potentially Deadly C. difficile Infections|
Click above to view more mutual fund data and stats for syn - Synthetic Biologics Inc.